Multicenter long-term safety efficacy study vigabatrin refractory complex partial seizures update patients refractory complex partial seizures favorable initial response median months Thirty-seven patients vigabatrin following reasons benefit-to-risk evaluation seizure breakthrough adverse events seizure breakthrough adverse events eligible study non-drug-related death narcotic abuse patient request significant abnormalities laboratory studies SMA complete blood count ECG EEG visual response testing toxicity reversible dose-dependent side effects long-term data clinical trials vigabatrin United Canada 